CalciMedica Inc
calcimedica.comWhat Do They Do?
Develops intravenous and oral CRAC-channel inhibitor drug candidates for acute inflammatory illnesses and chronic inflammatory or immunologic diseases, including pancreatitis and pulmonary arterial hypertension.
10-K for FY2025, filed Mar 3, 2026We are a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and…View ↗
Our lead product candidate is Auxora, a potent and selective, intravenously formulated small-molecule CRAC channel inhibitor containing the…View ↗
In parallel, we have generated preclinical data supporting the potential application of CRAC channel inhibition in both chronic and acute…View ↗
We are developing Auxora, an intravenous formulated small molecule CRAC channel inhibitor, for the treatment of acute inflammatory…View ↗
Oral CRAC channel inhibitors for chronic inflammatory and immunologic diseases. We have conducted exploratory preclinical research…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 3, 2026
How Are They Changing?
A shift in therapeutic focus
The business moved from developing medicines for retinal and optic-nerve diseases, including an eye gene therapy and a complement-pathway drug, to developing CRAC-channel inhibitors for acute and chronic inflammatory and immunologic diseases.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 3, 2026
Who Do They Compete With?
Competes with Rhizen Pharmaceuticals, Vivreon Biosciences, Medshine Discovery, Eldec Pharmaceuticals, ChemiCare, Ionis, Arrowhead, Panafina, SCM Lifsciences, Novartis, and AstraZeneca
10-K for FY2025, filed Mar 3, 2026We are a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious acute inflammatory illnesses driven…View ↗
Loading...
